Oxurion NV

The state of the financial markets for biopharmaceutical companies in 2024 is about as unpredictable as the weather in San Francisco during the annual J.P. Morgan Healthcare Conference. The forecast f

Once regarded as one of Europe's most promising biotechs, the curtain has fallen on Oxurion NV after the last diabetic eye disease drug in its pipeline failed a mid-stage trial. The Belgian ophthalm

Oxurion NV can chalk up another failure in diabetic macular edema (DME), this time for a drug that observers had hoped would make up for the last failed drug in the disease, though it has another pot

Tom Graney has been CEO of ophthalmic specialist Oxurion NV for just over a month but has already made his mark, narrowing the Belgian biotech's R&D focus in a restructuring that will also lead to j